PYXIS ONCOLOGY INC (PYXS)
US7473241013 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to PYXS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.16. This target is 80.93% above the current price.
PYXS was analyzed by 13 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about PYXS.
In the previous month the buy percentage consensus was at a similar level.
PYXS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-09 | BTIG | Initiate | Buy |
| 2024-01-23 | Leerink Partners | Initiate | Outperform |
| 2023-11-30 | HC Wainwright & Co. | Initiate | Buy |
| 2023-09-05 | RBC Capital | Initiate | Outperform |
| 2023-07-31 | EF Hutton | Initiate | Buy |
| 2023-03-23 | Credit Suisse | Reiterate | Outperform |
| 2021-11-02 | Credit Suisse | Initiate | Outperform |
| 2021-11-02 | B of A Securities | Initiate | Neutral |
| 2021-11-02 | Jefferies | Initiate | Buy |